EP2041165A2 - NOUVELLES APPLICATIONS DE LA PROTÉINE Sbi DE STAPHYLOCOCCUS AUREUS - Google Patents

NOUVELLES APPLICATIONS DE LA PROTÉINE Sbi DE STAPHYLOCOCCUS AUREUS

Info

Publication number
EP2041165A2
EP2041165A2 EP07733038A EP07733038A EP2041165A2 EP 2041165 A2 EP2041165 A2 EP 2041165A2 EP 07733038 A EP07733038 A EP 07733038A EP 07733038 A EP07733038 A EP 07733038A EP 2041165 A2 EP2041165 A2 EP 2041165A2
Authority
EP
European Patent Office
Prior art keywords
sbi
complement
binding
protein
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07733038A
Other languages
German (de)
English (en)
Inventor
Jean Department of Biology & Biochemistry VAN DEN ELSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bath
Original Assignee
University of Bath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bath filed Critical University of Bath
Publication of EP2041165A2 publication Critical patent/EP2041165A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Definitions

  • the system may contain "responder" cells capable of responding to one or more products of complement activation, such as anaphylatoxins (C3a and C5a) or opsonised targets (which may or may not be cells) carrying opsonins such as C3b.
  • responder cells are typically cells of the immune system and include basophils, neutrophils, mast cells, and macrophages .
  • the invention also provides use of a complement-binding protein comprising a Sbi-III domain capable of binding to C3 protein and/or a Sbi-IV domain capable of binding to C3 protein in the preparation of a medicament for the treatment of an inflammatory condition.
  • the complement-binding protein may comprise a Sbi- III-IV polypeptide.
  • Inhibition of B cell proliferation and/or antibody production may be useful in any inflammatory condition in which antibody production contributes to the pathogenesis or symptoms experienced. These include the inflammatory conditions set out above .
  • either the C3 protein or fragment or the complement-binding protein is preferably immobilised on a solid phase, and contacted with a sample containing the other protein.
  • the candidate compound under test may be introduced before, concurrently with, or after the sample containing the other protein component.
  • the invention further provides methods for detection or isolation of C3 and fragments thereof, e.g. in or from biological samples.
  • a method of detecting C3 or a fragment thereof in a sample, or isolating C3 or a fragment thereof from a sample comprising contacting said sample with a complement-binding protein comprising a Sbi-III domain capable of binding to said C3 or fragment thereof and/or a Sbi-IV domain capable of binding to said C3 or fragment thereof.
  • the method will typically comprise a step of removing any bound impurities or contaminants, e.g. by suitable washing.
  • the invention further provides a nucleic acid encoding a complement-binding protein comprising a Sbi-III domain capable of binding C3 protein, and/or a Sbi-IV domain capable of binding C3 protein, in the absence of a functional Sbi-I domain and/or a functional Sbi-II domain.
  • the invention further provides" a complement-binding protein comprising a Sbi-III domain capable of binding to C3 protein and/or a Sbi-IV domain capable of binding to C3 protein, or a nucleic acid encoding the same, or a vector or host cell containing such a nucleic acid, for use in a method of medical treatment.
  • the complement-binding protein may comprise a Sbi-III domain in the absence of Sbi-IV, or may comprise a Sbi-IV domain in the absence of Sbi-III, or may comprise a Sbi-III domain and a Sbi-IV domain.
  • it may comprise a Sbi-III-IV polypeptide.
  • FIG. 2a Experimental scattering curve of Sbi-E with error bars (1) and the scattering from the ab in ⁇ tio model (2) .
  • the plot displays the logarithm of the scattering intensity as a function of momentum transfer s.
  • the distance distribution function of Sbi-E calculated from the experimental data by the program GNOM is presented in the inset figure.
  • 2b A typical ab initio bead model of Sbi-E determined by DAMMIN 14 .
  • the 4 major globular domains are depicted with Roman numerals.
  • a homology model of Sbi domains I and II (shown in surface and ribbon representations) is superimposed onto the ab initio SAXS structure.
  • Figure 5a Sensorgrams showing the relative binding between sensorchip imised Sbi-III-IV (-1200 RU) and complement C3 derivatives: native 03, C3b, iC3b, C3c, C3dg, methylamine-reacted C3 (03(NHCH 3 )), iC3 (NHCH 3 ) and trypsinised 03 (NHCH 3 ) (denoted
  • Either type of complement-binding protein may possess further Sbi sequences derived from upstream (N-terminal) of the Sbi-III domain, including a Sbi-II domain, and/or a Sbi-I domain. Additionally or alternatively, they may possess further Sbi sequence derived from downstream (C-terminal) of the Sbi-IV domain, such as the cell wall-spanning sequence and/or Y region. However it is generally preferred that they do not possess Sbi-I or Sbi-II domains, or the cell wall-spanning or Y domains.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne la protéine Sbi de Staphylococcus aureus. Il s'est avéré que la protéine Sbi peut se fixer au complément C3 et à des fragments protéolytiques de celui-ci et qu'elle est capable, par conséquent, d'inhiber les trois voies d'activation du complément (c'est-à-dire la voie classique d'activation, la voie alternative d'activation et la voie de la lectine). Ainsi, l'invention concerne des procédés et des compositions destinés à l'inhibition du système du complément et au traitement de troubles inflammatoires se caractérisant par une activation indésirable de la voie d'activation du complément.
EP07733038A 2006-05-31 2007-05-31 NOUVELLES APPLICATIONS DE LA PROTÉINE Sbi DE STAPHYLOCOCCUS AUREUS Withdrawn EP2041165A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0610776A GB0610776D0 (en) 2006-05-31 2006-05-31 Novel applications for staphylococcus aureus Sbi protein
PCT/GB2007/002022 WO2007138328A2 (fr) 2006-05-31 2007-05-31 NOUVELLES APPLICATIONS DE LA PROTÉINE Sbi DE STAPHYLOCOCCUS AUREUS

Publications (1)

Publication Number Publication Date
EP2041165A2 true EP2041165A2 (fr) 2009-04-01

Family

ID=36694713

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07733038A Withdrawn EP2041165A2 (fr) 2006-05-31 2007-05-31 NOUVELLES APPLICATIONS DE LA PROTÉINE Sbi DE STAPHYLOCOCCUS AUREUS

Country Status (5)

Country Link
EP (1) EP2041165A2 (fr)
AU (1) AU2007266813A1 (fr)
CA (1) CA2653668A1 (fr)
GB (1) GB0610776D0 (fr)
WO (1) WO2007138328A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
GB201016403D0 (en) * 2010-09-29 2010-11-10 Bath Ventures Novel interaction between staphylococcus aureus Sbi and C3d protiens
WO2012095519A1 (fr) * 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Inhibiteurs puissants de l'activation du complément
SG10201604559TA (en) * 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
WO2013142349A1 (fr) * 2012-03-23 2013-09-26 University Of Chicago Compositions et méthodes associées à la sbi staphylococcique
GB201619965D0 (en) 2016-11-25 2017-01-11 Univ Of Bath The Immunogenic compositions comprising sbi protein and uses thereof
IL305333A (en) 2021-03-04 2023-10-01 Helix Nanotechnologies Inc Compositions comprising SBI adjuvant materials and methods of using them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704141D0 (sv) * 1997-11-12 1997-11-12 Sbl Vaccin Ab New protein and nucleotide sequence, encoding said protein
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
JP4404627B2 (ja) * 2001-08-02 2010-01-27 ユニヴァーシティー オヴ シェフィールド 抗原性ポリペプチド
KR101505496B1 (ko) * 2004-09-22 2015-03-25 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007138328A3 *

Also Published As

Publication number Publication date
AU2007266813A1 (en) 2007-12-06
CA2653668A1 (fr) 2007-12-06
GB0610776D0 (en) 2006-07-12
WO2007138328A3 (fr) 2008-05-08
WO2007138328A2 (fr) 2007-12-06

Similar Documents

Publication Publication Date Title
EP2041165A2 (fr) NOUVELLES APPLICATIONS DE LA PROTÉINE Sbi DE STAPHYLOCOCCUS AUREUS
JP6076326B2 (ja) 変異ｈ因子結合タンパク質を含むワクチン組成物
Burman et al. Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by Staphylococcus aureus
Rooijakkers et al. Staphylococcal complement inhibitor: structure and active sites
Seele et al. The immunoglobulin M-degrading enzyme of Streptococcus suis, Ide Ssuis, is involved in complement evasion
AU2006277076B2 (en) Interaction of Moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
Dutta Ray et al. Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H. 8 and Laz lipoproteins
JP7320585B2 (ja) 診断的および治療的使用を有するタンパク質
EP1290019A2 (fr) Utilisation d'un echafaudage structural a superhelice afin de generer des peptides specifiques de structure
Hallstrom et al. Haemophilus influenzae interacts with the human complement inhibitor factor H
Hallström et al. Immune evasion of Moraxella catarrhalis involves ubiquitous surface protein A-dependent C3d binding
JP2016147867A (ja) Ｏｐｒｆ／ｉ試薬と入院および他の患者におけるその利用
KR20170068456A (ko) OprF 및 OprI에 결합하는 항체 치료제
AU2014270598B2 (en) Generation of highly potent antibodies neutralizing the LukGH (LukAB) toxin of Staphylococcus aureus
JP2021527439A (ja) 補体阻害剤及びその使用
US20060246083A1 (en) Protective antigen of group a streptococci
AU2010236145A1 (en) New methods of making an antibody and compositions thereof
CA2353802C (fr) Nouvel antigene protecteur de streptococci du groupe a
WO2016073860A1 (fr) Molécules de liaison spécifique de la protéine a de staphylococcus et leurs utilisations
JP2014516028A (ja) ラミニン及びビトロネクチン結合特性を有するタンパク質ｆ−新規インフルエンザ菌付着因子
US20110046075A1 (en) Secreted Staphylococcus Aureus Proteins And Peptides For Use In Inhibiting Activation Of The Complement System
JP2002522055A (ja) バクテリア性超抗原ワクチン
WO2012042213A1 (fr) Nouvelle interaction entre les protéines sbi et c3d de staphylococcus aureus
Du Investigation of the role of Streptococcus pneumoniae surface proteins PspA and PspC
Jones Mechanisms responsible for differential bactericidal activities of human and rabbit complement against Neisseria meningitidis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081223

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20080508

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091201